High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia

Neurology

Volumn 48, Issue 5, 1997, Pages 1212-1218

  Nelson, Kristine A ^a,b   Park, Karen M ^a   Robinovitz, Elaine ^b   Tsigos, Constantine ^c   Max, Mitchell B ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROMETHORPHAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL;

EID: 0030992921     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.5.1212     Document Type: Article

References (49)

1. Tal M, Bennett G. Dextrorphan relieves neuropathic heat-evoked hyperalgesia in the rat. Neurosci Lett 1993;151:107-110.
2. Yamamoto T, Yaksh T. Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett 1992;135:67-70.
3. Kristensen JD, Karlsten R, Gordh T, Berge O. The NMDA antagonist 3-(2-carboxypiperazin-4yl)propyl-1-phosphonic acid (CPP) has antinociceptive effect after intrathecal injection in the rat. Pain 1994;56:59-67.
4. Kristensen JD, Post C, Gordh T, Svensson B. Spinal cord morphology and antinociception after chronic intrathecal administration of excitatory amino acid antagonists in the rat. Pain 1993;54:309-316.
5. Kristensen J, Svensson B, Gordh T. The NMDA receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans. Pain 1992;51:249-253.
6. Backonja M, Arndt G, Gombar K, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 1994;56:51-57.
7. Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 1995;37:1080-1087.
8. Eide P, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, crossover comparison with morphine and placebo. Pain 1994;58:347-354.
9. Eide P, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post herpetic neuralgia. Pain 1995;61:221-228.
10. Max MB, Byas-Smith MG, Gracely RH, Bennett GJ. Intravenous infusion of the NMDA antagonist, ketamine, in chronic post-traumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 1995;18:360-368.
11. Rogawski M. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. TIPS 1993:14;39-45.
12. Chen H, Pellegrini J, Aggarwal S, et al. Open channel block of N-methyl-D-asparate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992;12:4427-4436.
13. Blake P, Yamaguchi S, Thurkauf A, Rogawski M. Anticonvulsant 1-phenylcycloalkylamines: two analogues with low motor toxicity when orally administered. Epilepsia 1992;33:188-194.
14. Leander J, Rathbun R, Zimmerman D. Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D-aspartic antagonism. Brain Res 1988;454:368-372.
15. Parsons C, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacol 1995;34:1239-1258.
16. Tortella F, Pellicano M, Bowery N. Dextromethorphan and neuromodulation: old drug coughs up new activities. TIPS 1989;10:501-507.
17. Craviso G, Musacchio J. High affinity dextromethorphan binding sites in guinea pig brain. Mol Pharmacol 1983;23: 619-628.
18. Bern J, Peck R. Dextromethorphan: an overview of safety issues. Drug Safety 1992;7:190-199.
19. Cavanagh RL, Gylys JA, Bierwagen ME. Antitussive properties of butorphanol. Arch Int Pharmacodyn Ther 1976;220: 258-268.
20. Price D, Mao J, Frenk H, Mayer D. The N-methyl-D-asparate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 1994;59: 165-174.
21. McQuay H, Carroll D, Jadad A, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomized controlled crossover trial with integral n-of-1 design. Pain 1994;59:127-133.
22. Sternberg G, Bell T. Clinical dose-escalation safety study of the NMDA antagonist, dextromethorphan in neurosurgical patients [abstract]. Stroke 1991;22:141.
23. Walker F, Hunt V. An open label trial of dextromethorphan in Huntington's disease. Clin Neuropharmacol 1989;12:322-330.
24. Folstein M, Folstein S. Mini mental state. J Psychiatr Res 1975;12:189-195.
25. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057.
26. Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: consensus report of the peripheral nerve society. Ann Neurol 1995;38:478-482.
27. Olney J, Labruyere J, Wang G, et al. NMDA antagonist neurotoxicity: mechanisms and prevention. Science 1991;254: 1515-1518.
28. Gracely R, McGrath P, Dubner R. Ratio scales of sensory and affective verbal pain descriptors. Pain 1978;5:5-18.
29. Heft M, Gracely R, Dubner R, McGrath P. A validation model for verbal descriptor scaling of human clinical pain. Pain 1980;9:363-373.
30. Heft MW, Gracely RH, Dubner R. Nitrous oxide analgesia: a psychophysical evaluation using verbal descriptor scaling. J Dent Res 1984;63:129-132.
31. Gracely RH, Dubner R, McGrath PA. Fentanyl reduces the intensity of painful tooth pulp sensations: controlling for detection of active drugs. Anesth Analg 1982;61:751-755.
32. Max MB, Lynch S, Muir J, et al. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.
33. Max MB, Kishore-Kumar R, Schafer S, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991;45:3-9.
34. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-596.
35. Kishore-Kumar R, Max MB, Schafer S, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990;47: 305-312.
36. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988;38:1427-1432.
37. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage "enriched enrollment" design. Pain 1995;60: 267-274.
38. Pocock S. Clinical trials, a practical approach. New York: John Wiley and Sons, 1983:116-117.
39. Temple R. Dose-response and registration of new drugs. In: Lasagna L, Erill S, Naranjo CA, eds. Dose-response relationships in clinical pharmacology. Amsterdam: Elsevier, 1989: 145-170.
40. Max MB. Neuropathic pain. In: Max MB, Portenoy RK, Laska EM, eds. The design of analgesic clinical trials. Adv Pain Res Ther, vol 18. New York: Raven Press, 1991:193-220.
41. Watson CPN, Evans RJ, Reed K, Merskey H, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32:671-673.
42. Rowbotham M, Reisner-Keller L, Fields H. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:1024-1028.
43. Kastrup J, Petersen P, Dejgaard A, Angelo HR, Hilsted J. Intravenous lidocaine infusion - a new treatment of chronic painful diabetic neuropathy? Pain 1987;28:69-75.
44. Marchettini P, Lacerenzo M, Marangoni C. Lidocaine test in neuralgia. Pain 1992;48:377-382.
45. Dejgaard A, Petersen P, Kastrup J. Mexiletine for treatment of painful diabetic neuropathy. Lancet 1988;2:9-11.
46. Sugimoto T, Bennett G, Kajander K. Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: effects of a chronic constriction injury, transection, and strychnine. Pain 1990;42:205-213
47. Elliott K, Hynansky A, Inturrisi C. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 1994;59:361-368.
48. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-552.
49. Cherny N, Thaler H, Friedlander-Klar H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 1994;44:857-861.